Company intelligence / Profile preview

Anaconda Pharma

Ownership: Private
Development stage: Preclinical

Overview

Anaconda Pharma developed AP611074, a topical antiviral gel targeting HPV types 6 and 11. A Phase IIa trial demonstrated significant reduction in condyloma surface area with favorable tolerability. The company was acquired by Biota Pharmaceuticals in early 2015 to advance the program into further clinical development.[2][3][6]

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecules (topical antivirals)
Industry: Biotech

Beyond the preview

Go deeper on Anaconda Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaconda Pharma.

Explore the full profile